Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients (pts) with advanced NSCLC: Preliminary results of a phase II trial.

被引：0
|
作者：
Hanna, NH
Estes, D
Cress, A
Sidor, C
机构：
[1] Entremed, Rockville, MD USA
[2] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7105
引用
收藏
页码：642S / 642S
页数：1
相关论文
共 50 条
  • [1] Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University
    Kurup, A
    Lin, CW
    Murry, DJ
    Dobrolecki, L
    Estes, D
    Yiannoutsos, CT
    Mariano, L
    Sidor, C
    Hickey, R
    Hanna, N
    ANNALS OF ONCOLOGY, 2006, 17 (01) : 97 - 103
  • [2] Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers
    Karapanagiotou, E.
    Pandha, H. S.
    Hall, G.
    Chester, J.
    Melcher, A.
    Coffey, M.
    de Bono, J.
    Gore, M. E.
    Nutting, C. M.
    Harrington, K. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A comparative serum proteomic analysis of responders versus non-responders in a phase II study of recombinant human angiostatin (rhAngiostatin) protein plus carboplatin plus paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Kurup, A
    Hickey, RJ
    Dobrolecki, LE
    Rosenberg, LJ
    Pan, C
    Estes, DD
    Hanna, NH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 654S - 654S
  • [4] Preliminary results of phase II trial with combination of gemcitabine and oxaliplatin in elderly patients with advanced NSCLC.
    Buosi, R
    Poletti, S
    Cantele, V
    Piazza, S
    Torazzo, R
    Negru, E
    Vandone, A
    Alabiso, O
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 703S - 703S
  • [5] Preliminary assessment of a phase II study of paclitaxel and gemcitabine in combination in patients with advanced NSCLC.
    Isla, MD
    Martin, C
    González, LJL
    Felip, E
    Camps, C
    Carrato, A
    Antón, A
    Alberola, V
    Azagra, P
    Massutti, B
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S69 - S69
  • [6] Phase II trial of cetuximab (C225) in combination with monthly carboplatin (Cb) and weekly paclitaxel (Pac) in patients with advanced NSCLC: Promising early results
    Langer, Corey J.
    Ruth, Karen
    Borghaei, Hossein
    Treat, Joseph A.
    Shafer, Danielle
    Millenson, Michael
    Tuttle, Holly
    Rovito, Marc
    Mintzer, David
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S465 - S466
  • [7] Phase II trial of cetuximab (C225) in combination with monthly carboplatin (Cb) and weekly paclitaxel (Pac) in patients with advanced NSCLC: Promising early results
    Borghaei, H.
    Langer, C. J.
    Millenson, M.
    Tuttle, H.
    Seldomridge, J.
    Rovito, M.
    Mintzer, D.
    Treat, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy
    Flaherty, KT
    Stevenson, JP
    Hahn, SM
    Redlinger, M
    O'Dwyer, PJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (03) : 217 - 222
  • [9] Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy
    Keith T. Flaherty
    James P. Stevenson
    Stephen M. Hahn
    Maryann Redlinger
    Peter J. O'Dwyer
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 217 - 222
  • [10] Everolimus (RAD001C) in combination with carboplatin (C) and paclitaxel (P) as first line treatment for patients (pts) with advanced NSCLC: a phase I trial
    Papadimitrakopoulou, Vassiliki A.
    Malik, Shakun
    Brown, Michael P.
    Mitchell, Paul
    Thomas, Michael
    Mills, Glenn
    Pylaevanaeinen, Ilona
    Lilla, Di Scala
    Kunz, Tiffany
    Dimitrijevic, Sasa
    DeLeo, Jeffrey J.
    Korfee, Soenke
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S446 - S447
12345